Avalo Therapeutics is a clinical-stage biotech focused on monoclonal antibodies that block the IL-1β pathway in immune-mediated inflammatory disease. Its lead candidate, abdakibart (AVTX-009), is being developed for hidradenitis suppurativa, a chronic skin condition with limited treatment options. The pipeline also includes longer-acting next-generation anti-IL-1β antibodies. The company targets specialty dermatology and inflammatory indications rather than broad primary-care markets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -20.8 | — |
| Q3 2025 | 0 | — | -30.6 | — |
| Q4 2025 | 0.1 | — | -13.7 | — |
| Q1 2026 | 0 | — | -19.6 | — |
| Q2 2026 | 0 | — | -36.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Matthews International Corporation (MATW), Gilat Satellite Networks Ltd. (GILT), Super Hi International Holding Ltd. (HDL), NETGEAR, Inc. (NTGR), Stewards Inc. (SWRD), Climb Global Solutions, Inc. (CLMB)